Albumin Global Market Report 2024

Albumin is a type of protein present in blood plasma, serum, muscle, egg whites, milk, and other animal substances, as well as in various plant tissues and fluids. It is a simple protein that is heat-coagulable and water-soluble, playing a vital role in maintaining fluid balance and transporting hormones, vitamins, and enzymes throughout the body.

The primary types of albumin are human serum albumin, bovine serum albumin, and recombinant serum albumin. Human serum albumin, found in blood plasma, helps maintain osmotic pressure and transports various substances such as hormones and fatty acids. Its applications include therapeutics, drug formulation, vaccines, and media components, distributed through channels such as business-to-customer (B2C) and business-to-business (B2B). The end users of albumin include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.

The albumin research report is one of a series of new reports that provides albumin market statistics, including the albumin industry's global market size, regional shares, competitors with an albumin market share, detailed albumin market segments, market trends and opportunities, and any further data you may need to thrive in the albumin industry. This albumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The albumin market size has grown strongly in recent years. It will grow from $6.03 billion in 2023 to $6.57 billion in 2024 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be credited to advancements in biotechnology, a higher demand for plasma-derived therapies, expanding pharmaceutical applications, a high prevalence of liver diseases, regulatory approvals for albumin-based products, and the globalization of healthcare, which has led to wider market access.

The albumin market size is expected to see strong growth in the next few years. It will grow to $9.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth expected in the forecast period can be attributed to the increasing prevalence of liver diseases, expanding applications in regenerative medicine, a rising geriatric population, evolving diagnostic techniques, a shift in healthcare infrastructure towards outpatient care, and growing awareness about the importance of maintaining optimal protein levels. Major trends during the forecast period include expanding therapeutic applications, increasing adoption in drug delivery systems, higher demand in cell culture media, growth in personalized medicine, advancements in recombinant technology, heightened awareness of hypoalbuminemia treatment, and significant investment in research and development for innovative albumin-based products.

The increasing prevalence of diabetes is poised to drive growth in the albumin market moving forward. Diabetes, a metabolic disorder characterized by prolonged high blood sugar levels, is on the rise due to factors such as poor nutrition, sedentary lifestyles, hormonal conditions, and obesity. Albumin plays a critical role in diabetes management as a significant biomarker, guiding insulin therapy, monitoring glycemic control, aiding diagnosis, and predicting complications such as diabetic ketoacidosis (DKA). Maintaining normal albumin levels is crucial for effectively managing diabetes. According to the National Library of Medicine, global diabetes prevalence was estimated at 10.5% in 2021, affecting approximately 536.6 million individuals aged 20-79 years. Projections suggest this figure could reach 12.2% by 2045, impacting about 783.2 million people. Therefore, the rising incidence of diabetes is expected to drive growth in the albumin market.

Leading companies in the albumin market are focusing on innovation, developing products such as animal- and human-origin-free recombinant albumin to meet increasing demand with advanced features. This type of albumin is produced using non-mammalian expression systems such as yeast and does not contain any animal- or human-derived components. For example, in March 2023, Albumedix, a UK-based manufacturer of recombinant human albumin (rHA), collaborated with Heartseed Inc., a Japan-based clinical-stage biotech company, to introduce Recombin as a critical excipient for Heartseed's investigational cell therapy, HS-001, during its first-in-human clinical trial. This partnership represents a significant milestone in advancing HS-001, promising innovative treatment approaches for various diseases. The use of recombinant technology ensures optimal performance and stability of the cell therapy, enhancing its potential for therapeutic success.

In September 2022, Sartorius AG, a Germany-based supplier of pharmaceutical and laboratory equipment, acquired Albumedix, strengthening its position in the expanding sector of advanced therapies and vaccines. This acquisition aligns Albumedix's innovative recombinant albumin technology with Sartorius' portfolio of cell culture media and process solutions, bolstering the company's offerings in the dynamic market landscape of advanced therapies. Albumedix Ltd. is a UK-based provider of high-quality recombinant human albumin solutions.

Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.

North America was the largest region in the albumin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the albumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The albumin market consists of sales of egg albumin, plant-based albumin, and recombinant human albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.